

VESICON 2026 ABSTRACT SUBMISSION GUIDELINES

The abstract submission guidelines for VESICON 2026 are designed to provide authors with clear and comprehensive instructions for preparing and submitting their abstracts. All participants are strongly encouraged to read these guidelines carefully before beginning the submission process. The VESICON 2026 Scientific Committee and the Organizing Committee reserve the right to reject any abstract that does not adhere to the guidelines outlined below.

The VESICON 2026 Scientific Committee invites researchers to submit abstracts adhering to the guidelines outlined below. All authors are requested to read these instructions carefully before initiating the submission process. Abstracts that do not comply with these guidelines may be returned or rejected.

- 1. Alignment With MISEV2023 Guidelines:** Authors must ensure that their abstract follows the principles of the **Minimal Information for Studies of Extracellular Vesicles (MISEV2023)**. This includes appropriate use of EV nomenclature, accurate reporting of sample processing, separation/isolation methods, characterization practices, functional studies, and data interpretation.
- 2. Word Limits and Required Structure:**
 - The abstract title must not exceed 35 words.
 - The abstract body must not exceed 350 words.
 - All abstracts must be structured under the following subheadings: Introduction, Methods, Results, Summary/Conclusions.
 - The abstract in Word (.doc/docx) file format must be uploaded.
- 3. Formatting Requirements:**
 - Only the first letter of the first word in the title should be capitalized, except for abbreviations or proper nouns.
 - Do not end the title with a period.
 - Example of correct formatting: *“This abstract is about CD63-positive EVs”*.
 - Ensure clear separation of each section using the required subheadings
- 4. Originality of Scientific Content:** Abstracts must present original scientific or clinical data that have not been previously published or presented at any national or international meeting. Submissions without original data may be rejected.
- 5. Authorship and Submission Responsibility:** The submitting author must ensure that:
 - All co-authors have reviewed and approved the final abstract.
 - Complete author details (Name, Affiliation, City, Country, and Contact Information) are provided.

- The **Presenting Author** is clearly identified.
- Please gather all author information **before** beginning the submission process.

6. Molecular Nomenclature and Disclosure: All molecular findings must be described using accepted consensus names. Avoid placeholder terms such as “Protein X,” “Marker Y,” or “miRNA Z.” Abstracts lacking clear molecular identification may be rejected. If disclosure is restricted due to an ongoing or pending patent, please state this clearly within the abstract.

Important Dates & Deadlines

Event	Date	Notes / Time Zone
Abstract Launch	15 th March 2026	-
Abstract Submission Deadline	30 th April 2026	05.00 PM Indian Time
Author Notification Period	15 th May 2026	05.00 PM Indian Time
Presenting Author Registration Deadline	31 st May 2026	05.00 PM Indian Time
Registration Launch	15 th March 2026	-
Early Bird Registration Deadline	31 st May 2026	05.00 PM Indian Time
Late Registration Deadline	31 st Aug 2026	05.00 PM Indian Time
On-Spot Registration		